Biocept, Inc. short interest in 2018
In 2018, Biocept, Inc.'s disclosed short interest ran from 8.19% of shares outstanding on 12 Jan 2018 to 12.11% on 14 Dec 2018, a change of +3.92 percentage points. The year's high was 19.26% on 31 Oct 2018 and its low 6.24% on 30 Nov 2018, averaging 10.68% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.06 days on 15 May 2018. Full history: Biocept, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023
2018 in figures
- Start of year
- 8.19% (12 Jan 2018)
- End of year
- 12.11% (14 Dec 2018)
- Change
- +3.92 pp
- High
- 19.26% (31 Oct 2018)
- Low
- 6.24% (30 Nov 2018)
- Average
- 10.68%
- Highest days to cover
- 6.06 (15 May 2018)
- SEC filings marked
- 8
Every report in 2018
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2018 | 8.19% | 3.74 | |
| 31 Jan 2018 | 9.67% | 1.09 | |
| 15 Feb 2018 | 14.78% | 2.25 | |
| 28 Feb 2018 | 15.15% | 2.58 | |
| 15 Mar 2018 | 14.37% | 1.00 | |
| 29 Mar 2018 | 7.54% | 1.53 | 10-K filed, results (8-K) |
| 13 Apr 2018 | 8.43% | 4.30 | |
| 30 Apr 2018 | 8.35% | 5.00 | |
| 15 May 2018 | 7.96% | 6.06 | 10-Q filed, results (8-K) |
| 31 May 2018 | 7.78% | 4.29 | |
| 15 Jun 2018 | 8.96% | 4.79 | |
| 29 Jun 2018 | 8.18% | 3.17 | |
| 15 Aug 2018 | 13.08% | 2.13 | 10-Q filed, results (8-K) |
| 31 Aug 2018 | 12.48% | 1.17 | |
| 14 Sep 2018 | 9.62% | 2.66 | |
| 28 Sep 2018 | 11.23% | 1.19 | |
| 15 Oct 2018 | 14.30% | 1.48 | |
| 31 Oct 2018 | 19.26% | 1.10 | |
| 15 Nov 2018 | 6.55% | 4.01 | results (8-K), 10-Q filed |
| 30 Nov 2018 | 6.24% | 2.27 | |
| 14 Dec 2018 | 12.11% | 2.03 |
See also: Biocept, Inc.'s full history · most shorted US stocks of 2018 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.